Commentary|Articles|November 18, 2026

Oncologists Weigh Age and Drug Interactions in mHSPC Treatment Selection

Fact checked by: Matt Flowers
Listen
0:00 / 0:00

During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.

For men with metastatic hormone-sensitive prostate cancer (mHSPC), phase 3 trials support adding an androgen receptor pathway inhibitor (ARPI) to androgen deprivation therapy (ADT), and 4 agents have that support. None has been compared with another in a randomized trial, so the choice often turns on adverse events in men in their 70s and 80s, interactions with the cardiovascular and metabolic drugs these patients already take, and cost.

In a live Community Case Forum event in Pittsburgh, Pennsylvania, Zahra Kelly, DO, a medical oncologist and hematologist at UPMC Hillman Cancer Center, reviewed the pivotal doublet data and post hoc quality-of-life, cognition, and age-subgroup analyses and moderated discussion of a 74-year-old man with a pelvic node and a single bone lesion after prostatectomy. Kelly led a discussion about how each oncologist makes the decision in clinic.

Register today to join a Case-Based Roundtable near you.

This article is part 1 of a 2-part series from a Community Case Forum event.

CASE SUMMARY

  • A 74-year-old man with an active lifestyle and no family history of prostate cancer presents with mild urinary hesitancy and nocturia. Patient denies significant fatigue and weight loss. Patient walks 2-3 miles daily and participates in weekly golf. He lives with his spouse and values maintaining his physical activity.
  • Past medical history (PMH): Diabetes, hypertension, and hyperlipidemia. All well controlled with medication
  • Transrectal ultrasound (TRUS) and biopsy reveal adenocarcinoma of the prostate gland; Gleason score 7 [3+4] with disease in 3/12 cores
  • Notable labs: prostate-specific antigen (PSA) 12 ng/mL; hemoglobin (Hb) 12.8 g/dL; absolute neutrophil count (ANC) 2.4
  • Prostate-specific membrane antigen (PSMA) PET imaging shows no evidence of metastatic disease
  • Diagnosis: localized prostate cancer
  • He undergoes robotic radical prostatectomy (RP); subsequent PSA (<0.1 ng/mL)
  • Postoperatively, patient recovers well but reports mild stress urinary incontinence, requiring 1 pad per day, and erectile dysfunction, which he finds distressing but manageable
  • Imaging: post-RP CT and bone scintigraphy show no residual disease
  • Patient gradually returns to baseline activity, but he notes some ongoing impact on quality of life
  • Eighteen months later: PSA 6.2 ng/mL; Hb 12.5 g/dL; ANC 2.2
  • Imaging: PSMA PET imaging shows one avid pelvic lymph node and a single metastatic lesion in the left iliac bone
  • Patient remains asymptomatic with an ECOG performance status (PS) 0, but expresses concerns about preserving independence, avoiding treatment-related fatigue, and avoiding frequent clinic visits
  • Diagnosis: metastatic prostate cancer
  • Germline and somatic genetic testing are negative
  • He is referred to a medical oncologist
  • Therapeutic options were reviewed with the patient as part of shared decision-making
  • He prefers oral therapy and wishes to avoid chemotherapy; patient prioritizes minimizing adverse effects and maintaining quality of life

EVENT RECAP

Asked which systemic therapy they would recommend, 50% of 8 respondents chose ADT plus darolutamide (Nubeqa), 25% chose ADT plus abiraterone acetate (Zytiga) and prednisone, 12.5% chose ADT plus enzalutamide (Xtandi), and 12.5% chose another option. None chose ADT plus apalutamide (Erleada). Bana Antonios, MD, of Allegheny Health Network in Pittsburgh, Pennsylvania, who voted for another option, said this patient might be a “candidate for any trials or radiation to these oligo[metastatic] sites plus ADT,” given his wish to limit clinic visits. Kelly agreed that the field is moving toward metastasis-directed therapy.

For darolutamide without docetaxel, the registration study is the phase 3 ARANOTE trial (NCT04736199). Darolutamide plus ADT significantly reduced the risk of radiological progression or death vs placebo plus ADT, the primary end point (HR, 0.54; 95% CI, 0.41-0.71).1 The overall survival (OS) HR of 0.81 (95% CI, 0.59-1.12) was not statistically significant, and grade 3 or 4 treatment-emergent adverse events occurred in 30.8% of patients receiving darolutamide.The doublet trials enrolled different populations in different eras, so their results cannot be compared directly.

Jason Bierenbaum, MD, of UPMC in Pittsburgh, Pennsylvania, made the same point about efficacy but said tolerability comparisons are less of a concern. “In personal experience and the trials, I think [darolutamide] is clearly better tolerated,” he said, adding that he prescribes it for almost all his patients. Kevin Kane, MD, of Hillman Cancer Center in Allison Park, Pennsylvania, agreed, citing drug interactions and tolerance. Antonios said most patients in this age group take several medications, so the team messages its pharmacists before ordering. On cost, Bierenbaum noted that abiraterone is an inexpensive generic, though he rarely has coverage problems with the branded agents.

In ARANOTE, darolutamide was associated with longer time to pain progression (HR, 0.72; 95% CI, 0.54-0.96), a secondary end point, and longer time to deterioration in the Functional Assessment of Cancer Therapy–Prostate total score (median, 16.6 months vs 11.5 months; HR, 0.76; 95% CI, 0.61-0.94), an exploratory end point.2 In a post hoc analysis by age, grade 3 or 4 adverse events occurred in 33.3% of patients aged 75 years or older receiving darolutamide vs 33.9% receiving placebo, a descriptive comparison.3

In the randomized phase 2 ARACOG trial (NCT04335682), which compared darolutamide with enzalutamide in advanced prostate cancer, the maximally changed cognitive domain declined more with enzalutamide at the primary 24-week analysis (median change, −36.1 with enzalutamide vs −15.8 with darolutamide; P = .009), and 4 of 5 individual domains favored darolutamide.4

In the STOPCAP individual participant data meta-analysis, the OS HR for adding an ARPI was 0.63 (95% CI, 0.56-0.71) in patients younger than 65 years and 0.77 (95% CI, 0.66-0.90) in those 75 or older, an interaction that did not reach statistical significance (P = .052).5 In the oldest group, the estimated 5-year absolute OS benefit was about 0% with abiraterone vs about 19% in the amide trials, an exploratory analysis.5 Kelly asked whether abiraterone is “something that we should think twice about in patients who are older than 75.” She noted that the finding came from a retrospective meta-analysis and that more work is needed.

Kelly also reviewed ARASEC (NCT05059236), a phase 2 open-label study that compared 160 patients receiving darolutamide plus ADT with 160 propensity-matched patients from the ADT-alone arm of an earlier trial. Darolutamide was associated with longer progression-free survival (HR, 0.29; 95% CI, 0.20-0.40) and OS (HR, 0.50; 95% CI, 0.30-0.82; P = .003), and 68% vs 33% of patients reached a PSA below 0.2 ng/mL at any time, all statistically significant differences.6 Because the control arm came from a different trial and era, the results cannot be compared directly with those of a randomized study. Asked what PSA response she watches, Kelly said, “I personally look at PSA of less than [0.2 ng/mL]. I think it’s fairly prognostic,” typically at 3 to 6 months.

Still, 75% of 8 respondents said they use ADT alone for some patients. Kelly said patients in their late 80s and early 90s may start on ADT alone and have ARPI added if they tolerate it.

With efficacy across the agents hard to separate, participants treated drug interactions and tolerability in older men as the deciding considerations, while abiraterone’s low cost as a generic keeps it in use. Whether the STOPCAP age signal should change prescribing remained an open question for the group.

Register today to join a Case-Based Roundtable near you.

DISCLOSURES: There were no known relevant disclosures.

REFERENCES
1. Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271-4281. doi:10.1200/JCO-24-01798
2. Morgans AK, Haresh KP, Jievaltas M, et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026;27(5):614-624. doi:10.1016/S1470-2045(26)00014-8
3. Saad F, Morgans AK, Shore ND, et al. Darolutamide efficacy, quality of life, and safety outcomes by age subgroup: ARANOTE post hoc analyses. Ann Oncol. 2025;36(suppl 2). Abstract 2459P.
4. Morgans AK, Bobek O, Kwon DH, et al. Cognitive effects of darolutamide vs enzalutamide: results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology. J Clin Oncol. 2026;44(suppl 16):5005. doi:10.1200/JCO.2026.44.16_suppl.5005
5. Fisher DJ, Vale CL, Rydzewska LH, et al. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). J Clin Oncol. 2025;43(suppl 5):20. doi:10.1200/JCO.2025.43.5_suppl.20
6. McKay RR, Ross AE, Preston MA, et al. Darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): ARASEC – US prospective, open-label phase 2 study with an external control arm. Presented at: American Urological Association Annual Meeting; May 15-18, 2026; Washington, DC.

Related to this article